2024【買淘寶家具 5 個重點】為自己打造夢幻生活空間不再是夢！

Role of etelcalcetide in the management of secondary ... | 合法藥品大搜索

Role of etelcalcetide in the management of secondary ...

Role of etelcalcetide in the management of secondary ...

1Department of Internal Medicine, Clinical Division of Nephrology, Medical University of Graz, Graz, 2Department of Internal Medicine III, Nephrology and Dialysis, Feldkirch Academic Teaching Hospital, Feldkirch, Austria

Abstract: Secondary hyperparathyroidism (sHPT) is a frequently occurring severe complication of advanced kidney disease. Its clinical consequences include extraskeletal vascular and valvular calcifications, changes in bone metabolism resulting in renal osteodystrophy, and an increased risk of cardiovascular morbidity and mortality. Calcimimetics are a cornerstone of parathyroid hormone (PTH)-lowering therapy, as confirmed by the recently updated 2017 Kidney Disease: Improving Global Outcomes chronic kidney disease – mineral and bone disorder clinical practice guidelines. Contrary to calcitriol or other vitamin D-receptor activators, calcimimetics reduce PTH without increasing serum-calcium, phosphorus, or FGF23 levels. Etelcalcetide is a new second-generatio...

閱讀更多

Etelcalcetide vs cinacalcet parsabiv Jama 2017 317 2 146 155 Etelcalcetide vs cinacalcet parsabiv Jama 2017 317 2 146 155 parsabiv仿單 parsabiv價格 旁必福parsabiv 旁必福價格 銳克鈣價錢 旁必福仿單 Parsabiv Etelcalcetide 氯黴素眼藥水用途 美商亞培股份有限公司台灣分公司統編 zytiga價錢 適汎黴素膠囊副作用 四環素副作用 安寧病房 查詢 塩野義ptt 鹽野義可樂喜定
Role of etelcalcetide in the management of secondary ... | 合法藥品大搜索
Read More
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid ... | 合法藥品大搜索
由 GA Block 著作 · 2017 · 被引用 168 次 — Meaning Etelcalcetide was more effective than cinacalcet in lowering PTH concentrations in patients receiving dialysis with secondary ... Read More
Dosing of Etelcalcetide vs Cinacalcet for Secondary ... | 合法藥品大搜索
由 GA Block 著作 · 2017 · 被引用 3 次 — We acknowledge that patients treated with etelcalcetide could have reached the maximum dose after 2-dose titrations whereas patients treated with cinacalcet ... Read More
Effect of Etelcalcetide vs Cinacalcet on Serum ... | 合法藥品大搜索
由 GA Block 著作 · 2017 · 被引用 168 次 — The estimated difference in proportions of patients achieving reduction in PTH concentrations of more than 30% between the 198 of 343 patients ( ... Read More
A Decision | 合法藥品大搜索
由 B Stollenwerk 著作 · 2018 · 被引用 10 次 — ... Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. Pharmacoeconomics. 2018 May;36(5):603-612. doi: 10.1007/s40273-017-0605-​2. Read More
Effect of switching from cinacalcet to etelcalcetide on ... | 合法藥品大搜索
由 Y Kurokawa 著作 · 2020 — showed that etelcalcetide is not superior to cinacalcet in terms of gastrointestinal adverse effects and substantially reduces iPTH levels [16]. Read More
Effect of Etelcalcetide vs Cinacalcet on Serum ... | 合法藥品大搜索
由 GA Block 著作 · 2017 · 被引用 168 次 — clinical trial was conducted comparing IV etelcalcetide vs oral placebo and oral cinacalcet vs. IV placebo in 683 patients receiving hemodialysis with serum ... Read More
Comparison between cinacalcet and etelcalcetide | 合法藥品大搜索
Etelcalcetide had the highest odds of achieving a PTH target compared with evocalcet (OR, 4.93; 95% CI, 1.33-18.2) and cinacalcet (OR, 2.78; 95% CI, 1.19-​6.67). Read More
Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in ... | 合法藥品大搜索
由 J Patel 著作 · 2018 · 被引用 5 次 — While etelcalcetide binds in the extracellular N-terminal domain of the CaSR, cinacalcet binds within the seven-transmembrane domain of the CaSR, indicating ... Read More
相關資訊整理

【旁必福注射液】PARSABIV適用於治療罹患慢性腎臟病 (CKD) 且接受血液透析之成人病人的次發性副甲狀腺機能亢進 (secondary HPT)。

藥品名稱:旁必福注射液許可證字號:衛部藥輸字第027639號許可證種類:製　劑適應症:PARSABIV適用於治療罹患慢性腎臟病(CKD)且...

【艾法施注射液】一、轉移性大腸直腸癌 ( mCRC )：(1)與含有 5-fluorouracil 為基礎的化學療法合併使用，可以作為轉移性大腸或直腸癌病人的第一線治療。(2)與含有 5-fluorouracil/leucovorin/oxaliplatin 的化學療法合併使用，可以作為先前接受過以 fluoropyrimidine 為基礎的化學療法無效且未曾接受過bevacizumab 治療的轉移性大腸或直腸癌病人的治療。(3)與含有fluoropyrimidine-irinotecan-或fluoropyrimidine-oxaliplatin- 為基礎的化學療法合併使用，可以做為第一線已接受過以MVASI 併用化療後惡化之轉移性大腸或直腸癌病人的第二線治療。二、轉移性乳癌 ( mBC )：與 paclitaxel 合併使用，可以做為 HER2 (-) 轉移性乳癌病人的第一線治療。三、惡性神經膠質瘤 ( WHO 第 4 級 ) - 神經膠母細胞瘤：單獨使用可用於治療曾接受標準放射線治療且含 Temozolomide 在內之化學藥物治療失敗之多型性神經膠母細胞瘤 ( Glioblastoma multiforme ) 復發之成人病人。四、晚期、轉移性或復發性非鱗狀非小細胞肺癌 ( NSCLC )：(1)與 carboplatin 及 paclitaxel 合併使用，可以作為無法切除的晚期、轉移性或復發性非鱗狀非小細胞肺癌病人的第一線治療。(2)併用 erlotinib，可作為無法手術切除的晚期、轉移性或復發性且帶有表皮生長因子受體 ( EGFR ) 活化性突變的非鱗狀非小細胞肺癌病人的第一線治療。五、持續性、復發性或轉移性之子宮頸癌 ( Persistent, Recurrent, or Metastatic Cervical Cancer )：(1)與 paclitaxel 及 cisplatin 合併使用可用於治療持續性、復發性或轉移性之子宮頸癌。(2)與 paclitaxel 及 topotecan 合併使用可用於無法接受含鉑類藥物治療( platinum therapy ) 病人之持續性、復發性或轉移性子宮頸癌。

藥品名稱:艾法施注射液許可證字號:衛部菌疫輸字第001117號許可證種類:菌　疫適應症:一、轉移性大腸直腸癌(mCRC)：(1)與含有5...

【福祿鈣片】缺鈣、齲齒

藥品名稱:福祿鈣片許可證字號:內衛藥製字第008220號許可證種類:製　劑適應症:缺鈣、齲齒劑型:藥品類別:醫師藥師藥劑生指示藥...

【銳克鈣錠25毫克】治療透析患者的次發性副甲狀腺機能亢進。

藥品名稱:銳克鈣錠25毫克許可證字號:衛署藥輸字第025141號許可證種類:製　劑適應症:治療透析患者的次發性副甲狀腺機能亢進。...

【鈣易清膜衣錠25毫克】治療透析患者的次發性副甲狀腺機能亢進。

藥品名稱:鈣易清膜衣錠25毫克許可證字號:衛部藥製字第058545號許可證種類:製　劑適應症:治療透析患者的次發性副甲狀腺機能亢...

【銳克鈣錠75毫克】治療透析患者的次發性副甲狀腺機能亢進。

藥品名稱:銳克鈣錠75毫克許可證字號:衛署藥輸字第025140號許可證種類:製　劑適應症:治療透析患者的次發性副甲狀腺機能亢進。...

【捷達外用液】香港腳、灰指甲、皮膚真菌引起之感染症

藥品名稱:捷達外用液許可證字號:衛署藥輸字第014548號許可證種類:製　劑適應症:香港腳、灰指甲、皮膚真菌引起之感染症劑型:...